Madrigal Pharmaceuticals (MDGL) Cash & Current Investments (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Cash & Current Investments for 17 consecutive years, with $838.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Current Investments rose 5.24% year-over-year to $838.8 million; the TTM figure through Jun 2026 stood at $838.8 million (up 5.24% YoY), while the FY2025 annual figure was $983.6 million, up 6.19% from the prior year.
• Cash & Current Investments rose to $838.8 million in Q2 2026 per MDGL's latest filing, from $812.8 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $1.1 billion in Q3 2025 and bottomed at $153.2 million in Q3 2022.
• Historically, Cash & Current Investments has averaged $659.2 million across 5 years, with a median of $804.9 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Current Investments plunged 48.79% — and 2024, when it jumped 329.79%.
• Madrigal Pharmaceuticals' Cash & Current Investments stood at $358.8 million in 2022, then surged by 76.75% to $634.1 million in 2023, then jumped by 46.07% to $926.3 million in 2024, then climbed by 6.19% to $983.6 million in 2025, then slipped by 14.72% to $838.8 million in 2026.
• Business Quant data shows MDGL's Cash & Current Investments at $838.8 million in Q2 2026, $812.8 million in Q1 2026, and $983.6 million in Q4 2025.